Seguici su

Myelofibrosis: facing the future by challenging the past

Myelofibrosis (MF) is experiencing a lively moment from a scientific point of view. As hypothesized in previous editions of the meeting, JAK2 inhibitors retain a backbone role in newer and promising therapeutic combinations that could undermine the pathogenic basis of MF. Biological data collected in clinical trials highlight the possibility of modulating some important features that drive disease aggressiveness, such as fibrosis, allelic burden of mutations, proinflammatory cytokines, and the microenvironment. The result is an overall improvement in clinical outcomes, which the scientific community is watching with increasing interest. This year’s congress aims to devise the best strategies for MF patients starting from their preclinical rationale.
  • Myelofibrosis: facing the future by challenging the past
  • 2022-11-17T15:00:00+01:00
  • 2022-11-18T19:00:00+01:00
  • Myelofibrosis (MF) is experiencing a lively moment from a scientific point of view. As hypothesized in previous editions of the meeting, JAK2 inhibitors retain a backbone role in newer and promising therapeutic combinations that could undermine the pathogenic basis of MF. Biological data collected in clinical trials highlight the possibility of modulating some important features that drive disease aggressiveness, such as fibrosis, allelic burden of mutations, proinflammatory cytokines, and the microenvironment. The result is an overall improvement in clinical outcomes, which the scientific community is watching with increasing interest. This year’s congress aims to devise the best strategies for MF patients starting from their preclinical rationale.
  • Quando dal 17/11/2022 15:00 al 18/11/2022 19:00
  • Dove Best Western Hotel Globus City Via Traiano Imperatore, 4 47122 Forlì
  • Sito web Visita il sito
  • Aggiungi l'evento al calendario iCal

Myelofibrosis (MF) is experiencing a lively moment from a scientific point of view. As hypothesized in previous editions of the meeting, JAK2 inhibitors retain a backbone role in newer and promising therapeutic combinations that could undermine the pathogenic basis of MF. Biological data collected in clinical trials highlight the possibility of modulating some important features that drive disease aggressiveness, such as fibrosis, allelic burden of mutations, proinflammatory cytokines, and the microenvironment. The result is an overall improvement in clinical outcomes, which the scientific community is watching with increasing interest. This year’s congress aims to devise the best strategies for MF patients starting from their preclinical rationale.

Azioni sul documento

ultima modifica 2022-10-07T10:54:57+01:00
Questa pagina ti è stata utile?

Valuta il sito

Non hai trovato quello che cerchi ?